Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of “Hold” by Analysts

Replimune Group, Inc. (NASDAQ:REPL) has been given an average recommendation of “Hold” by the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $10.00.

Several equities analysts recently commented on REPL shares. Piper Sandler upped their price target on shares of Replimune Group from $13.00 to $14.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Replimune Group in a research note on Monday, December 29th. Finally, Wedbush boosted their target price on Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th.

Replimune Group Price Performance

NASDAQ:REPL opened at $7.54 on Friday. The firm has a market capitalization of $622.60 million, a price-to-earnings ratio of -2.19 and a beta of 0.72. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The business has a 50 day simple moving average of $7.54 and a 200-day simple moving average of $7.74. Replimune Group has a 1 year low of $2.68 and a 1 year high of $13.24.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.08. Equities analysts forecast that Replimune Group will post -2.97 EPS for the current year.

Hedge Funds Weigh In On Replimune Group

Large investors have recently bought and sold shares of the business. International Assets Investment Management LLC bought a new position in Replimune Group in the 4th quarter valued at $29,000. Russell Investments Group Ltd. lifted its position in shares of Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after purchasing an additional 7,569 shares during the last quarter. CWM LLC lifted its position in shares of Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after purchasing an additional 2,886 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Replimune Group by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after purchasing an additional 6,873 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Replimune Group in the second quarter worth about $69,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.